Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P729: A ‘real-world’ retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

V. Kronsten1*, M. Colwill1, S. Nayeemuddin2, J. Limdi2,3, C. Selinger4, G. Scott5, L. Al-Hillawi6, S. Salehi6, P. Blaker6, G. Chung-Faye1, A. Kent1, P. Dubois1, B. Hayee1

1Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK, 2Department of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, UK, 3Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK, 4Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK, 5Department of Gastroenterology, East Kent Hospital University Foundation Trust, Margate, UK, 6Department of Gastroenterology, Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, UK

P730: High-dosed intravenous iron replacement therapy does not hinder drug-induced amelioration of disease activity in IBD patients with iron deficiency anaemiaECCO '18 Vienna
Year: 2018
Authors:

J. Stein1,2*, S. Vollmer3, W. Klemm4, K. Nip5, S. Weber-Mangal5, A. Dignass1,6

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Gastroenterological practice, Göppingen, Germany, 4Gastroenterological practice, Cottbus, Germany, 5Vifor Pharma Deutschland GmbH, Munich, Germany, 6Agaplesion Markus Krankenhaus, Department of Gastroenterology, Frankfurt/Main, Germany

P731: The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort studyECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, S. Rundquist1, Y. Cao2, S. Montgomery2, J. Halfvarson1*

1Faculty of Medicine and Health, Örebro University, Örebro, Sweden, 2Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden

P732: Disability in older IBD patientsECCO '18 Vienna
Year: 2018
Authors:

V. Asscher1*, L. Meijer1, S. Waars1, J. Slagboom1, A. Van der Meulen- de Jong1, S. Mooijaart2, J. Maljaars1

1LUMC, Gastroenterology-Hepatology, Leiden, The Netherlands, 2Lumc, Geriatrics and Gerontology, Leiden, The Netherlands

P733: Serum interleukin-6 level predicts future outcomes of infliximab for ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

Y. Nishida*, S. Hosomi, T. Yukawa, K. Otani, Y. Nagami, F. Tanaka, K. Taira, N. Kamata, H. Yamagami, T. Tanigawa, T. Watanabe, Y. Fujiwara

Osaka city university, gastroenterology, Osaka, Japan

P734: Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of lifeECCO '18 Vienna
Year: 2018
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

1IBD clinical and research centre, Iscare, Prague, Czech Republic, 2Department of Internal medicine, University Hospital Plzen, Plzen, Czech Republic, 3Department of Internal medicine, Thomayer University Hospital, Prague, Czech Republic, 4Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 5Department of Paediatric Surgery, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 6General paediatrician, Prague, Czech Republic

P735: Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Vermeire1*, M. Crowther2, V. Pradhan3, A. Banerjee3, F. Cataldi4, K. Gorelick5

1University Hospitals Leuven, Leuven, Belgium, 2McMaster University, Hamilton, Ontario, Canada, 3Pfizer, Cambridge, USA, 4Shire, Lexington, USA, 5Zymo Consulting Group, Newtown Square, USA

P736: Point-of-care infliximab quantification in inflammatory bowel disease in daily practiceECCO '18 Vienna
Year: 2018
Authors:

M.P. Costa Santos*, C. Palmela, C. Gouveia, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal

P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable resultsECCO '18 Vienna
Year: 2018
Authors:

R. Sagar1, M. Lenti1, T. Clark1, H. Rafferty1, D. Gracie1, A. Ford1, A. O'Connor1, J. Hamlin1, T. Ahmad2, C. Selinger1*

1St James University Hospital, Gastroenterology, Leeds, UK, 2Royal Devon and Exeter Foundation Trust, Gastroenterology, Exeter, UK

P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remittersECCO '18 Vienna
Year: 2018
Authors:

R. Hardi1, B. Bokemeyer2, W. Sandborn3, W. Reinisch4, I. Shafran5, A. Stallmach6, R. Ehehalt7, P. Geransar8*, J.M. Khalid9, D. Tudor10, S. Schreiber11

1Capital Digestive Care, Chevy Chase Clinical Research, Chevy Chase, USA, 2Gastroenterology Practice, Minden, Germany, 3University of California San Diego, Division of Gastroenterology, La Jolla, USA, 4Medical University of Vienna, Department Internal Medicine III, Vienna, Austria, 5Shafran Gastroenterology Research Center, Winter Park, USA, 6Jena University Hospital, Department of Internal medicine IV, Jena, Germany, 7Praxis für Gastroenterologie, Heidelberg, Germany, 8Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 9Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 10Takeda Pharmaceuticals International AG, Zurich, Switzerland, 11Christian-Albrechts-University, Institute for Clinical Molecular Biology, Kiel, Germany

P739: Early use of anti-TNF in Crohn’s disease is associated with higher rate of biological and endoscopic remissionECCO '18 Vienna
Year: 2018
Authors:

M.P. Costa Santos*, C. Gouveia, C. Palmela, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal

P740: Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experienceECCO '18 Vienna
Year: 2018
Authors:

C. González Muñoza1, F. Mesonero2, A. Bargalló3, A. Clos4, C. Aràjol5, J. Gordillo1*, A. López- San Román2, J. Guardiola5, M. Navarro-Llavat3, F. Bertoletti1, C. Fernández2, E. Domènech4,6, E. Garcia-Planella1

1Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 3Hospital Moisès Broggi, Sant Joan Despi, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 6Ciberehd, Madrid, Spain

P741: Very high rate of tuberculosis complicating infliximab therapy for inflammatory bowel disease despite tuberculosis screening in IndiaECCO '18 Vienna
Year: 2018
Authors:

A. Agarwal*, S. Kedia, S. Jain, V. Gupta, S. Bopanna, D. Yadav, S. Goyal, P.M. Venegella, G. Makharia, V. Ahuja

All India Institute Of Medical Sciences, Gastroenterology and Human Nutrition, New Delhi, India

P742: Long-term outcome of patients with ulcerative colitis and first course of intravenous corticosteroidsECCO '18 Vienna
Year: 2018
Authors:

H. Eronen1*, P. Oksanen1,2, A. Jussila1

1Tamperee University Hospital, Gastroenterology, Tampere, Finland, 2Tampere University, Tampere, Finland

P743: Ustekinumab use in Crohn´s Disease: Does short-term effectiveness correlate to induction regimen?ECCO '18 Vienna
Year: 2018
Authors:

A. Gutiérrez1,2*, L. Sempere1, R. Laveda3, M.F. García4

1Hospital General Universitario Alicante, Alicante, Spain, 2CIBERehd, Madrid, Spain, 3Hospital San Juan, Alicante, Spain, 4Hospital General Universitario Elche, Elche, Spain

P744: Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapyECCO '18 Vienna
Year: 2018
Authors:

S. Buhl*, M.K. Borghede, J. Brynskov, C. Steenholdt, M. Rasmussen, M.A. Ainsworth

Copenhagen University Hospital, Herlev, Department of Gastroenterology, Herlev, Denmark

P745: Switching between anti-TNF originator and biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewECCO '18 Vienna
Year: 2018
Authors:

J.P. Gisbert1,2,3,4*, M. Chaparro1,2,3,4

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

P746: Anthropometric measures in adolescents with inflammatory bowel disease: A population-based studyECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel

P747: Predictors of thiopurine treatment failure in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S.H. Hwang1*, J.S. Koo1, K.H. Kang1, D.-w. Lee1, B.J. Lee2, Y.T. Jeen3

1Korea University Ansan Hospital, Division of Gastroenterology and Hepatology, Ansan, South Korea, 2Korea University Guro Hospital, Division of Gastroenterology and Hepatology, Seoul, South Korea, 3Korea University Anam Hospital, Division of Gastroenterology and Hepatology, Seoul, South Korea

P748: Clinical outcomes and prognostic factors of methotrexate therapy in combination with anti-TNF agents in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Park1,2*, J.H. Cheon1,2, J.J. Park3, Y. Park1,2, S.J. Park1,2, T.I. Kim1,2, W.H. Kim1,2

1Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea, 2Yonsei University College of Medicine, Institute of Gastroenterology, Seoul, South Korea, 3Gangnam Severance Hospital, Yonsei University College of Medicine, Department of Internal Medicine, Institute of Gastroenterology, Seoul, South Korea